Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Other Accumulated Expenses: 2009-2022

Historic Other Accumulated Expenses for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $3.8 million.

  • Avadel Pharmaceuticals' Other Accumulated Expenses rose 155.40% to $3.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $3.8 million, marking a year-over-year increase of 155.40%. This contributed to the annual value of $5.3 million for FY2021, which is 1.35% up from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Other Accumulated Expenses of $3.8 million as of Q3 2022, which was up 83.18% from $2.1 million recorded in Q2 2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Other Accumulated Expenses peaked at $5.3 million during Q4 2021, and registered a low of $1.4 million during Q1 2022.
  • For the 3-year period, Avadel Pharmaceuticals' Other Accumulated Expenses averaged around $3.0 million, with its median value being $3.1 million (2021).
  • In the last 5 years, Avadel Pharmaceuticals' Other Accumulated Expenses surged by 509.72% in 2018 and then tumbled by 57.13% in 2021.
  • Avadel Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $3.6 million in 2018, then rose by 6.46% to $3.9 million in 2019, then spiked by 34.19% to $5.2 million in 2020, then rose by 1.35% to $5.3 million in 2021, then spiked by 155.40% to $3.8 million in 2022.
  • Its last three reported values are $3.8 million in Q3 2022, $2.1 million for Q2 2022, and $1.4 million during Q1 2022.